Look­ing to rein­vent those trou­bled AAVs you've been read­ing about, in­vestors back a $110M re­boot ef­fort

Next week, Affinia Ther­a­peu­tics will present four new ab­stracts at the Amer­i­can So­ci­ety of Gene and Cell Ther­a­py. Though they bear ob­scure and aca­d­e­m­ic names, they will pro­vide the first proof of con­cept for an ap­proach in­vestors have now poured $170 mil­lion in­to and that Affinia wants to get in the clin­ic next year.

Affinia, a 2019 spin­out from the lab of old Jim Wil­son pro­tégé Luk Van­den­berghe, an­nounced Mon­day that it raised a $110 mil­lion Se­ries B led by the biotech VC EcoR1 Cap­i­tal and the Tom Stey­er hedge fund Far­al­lon Cap­i­tal. Thir­teen oth­er in­vestors joined, in­clud­ing the blue-chip firms At­las, RA Cap­i­tal, Per­cep­tive Ad­vi­sors, Cas­din Cap­i­tal, F-Prime and GV.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER